Stay updated with breaking news from Corporate Developments Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Reports First Quarter 2021 Financial Results and Provides Business Update --ARIKAYCE® (amikacin liposome inhalation suspension) Approved in Japan for Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with a Multidrug Regimen-- --ARIKAYCE European Launch Under Way with Commercial Sales in Germany and the Netherlands-- --Enrollment Progresses in Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis and in Post-Marketing ARISE and ENCORE Studies of ARIKAYCE in Frontline NTM Lung Disease Caused by MAC-- --Treprostinil Palmitil In...